The Valley Desk

ArticleACS medicinal chemistry lettersPublished

Discovery of Potent 1,3-Cyclobutane-Containing Dual A2A/A2B Receptor Antagonists with Low Projected Human Dose for the Treatment of Cancer

11 of 32 authors shown in byline order.

Read the publication ↗ Open access copy ↗

Regional connection

Verified An author affiliation on the Europe PMC record names Merck & Co. Affiliation source

Institution
Merck & Co.

Publication record

Type
Article
Venue
ACS medicinal chemistry letters
Published
Subject terms
Combination therapy; Cancer Treatment; Triazoloquinazoline; A2a/a2b Receptor Antagonists
PubMed ID
42157841
PubMed Central ID
PMC13181494
Added to directory
Source checked

Report a correction or request removal